CAPR NASDAQ
Capricor Therapeutics, Inc.
1W: -7.7%
1M: -30.0%
3M: -7.2%
YTD: -78.5%
1Y: -1.6%
3Y: +121.0%
5Y: +54.0%
$6.10
+0.36 (+6.27%)
Weekly Expected Move ±13.9%
$4
$5
$6
$7
$8
Credit Risk of going bust: higher than 97% of companies Debt: 20.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.55 (down 91%), Capricor Therapeutics, Inc. would be worth roughly what it owes.
Total debt $91.0M against a stock market value of $353.3M.
Distance to default 0.05 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $45.5M (short-term plus half of long-term), stock volatility 216.5%; Altman Z'' 0.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.55 (down 91%), Capricor Therapeutics, Inc. would be worth roughly what it owes.
Total debt $91.0M against a stock market value of $353.3M.
Distance to default 0.05 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $45.5M (short-term plus half of long-term), stock volatility 216.5%; Altman Z'' 0.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-04-30
Earliest Filing
2024-09-17
Latest Filing
partner: 4
Counterparties (Filed by CAPR)
4 relationshipsCompanies named in CAPR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nippon Shinyaku, Co., Ltd. | — | partner | Partnered for European commercialization and distribution of deramiocel; invested $15M in private placement. | 2024-09-17 | View |
| Nippon Shinyaku, Co., Ltd. | — | partner | Exclusive commercialization and distribution partner for CAP-1002 in Japan | 2023-02-16 | View |
| Nippon Shinyaku, Co., Ltd. | — | partner | Exclusive commercialization and distribution agreement for CAP-1002 in the United States. | 2022-01-25 | View |
| Johns Hopkins University | — | partner | Entered into an Exclusive License Agreement with Capricor Therapeutics, Inc. for intellectual property rights related to | 2021-04-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-24 | Other Events; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-30 | Other Events; Exhibits | View | |
| 2026-07-29 | Other Events; Exhibits | View | |
| 2026-07-14 | Material Agreement; Financial Obligation | Agreement | View |
| 2026-06-26 | Other Events; Exhibits | View | |
| 2026-06-08 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-05-07 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-27 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-08 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR